查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837129

旅行疫苗市场（按疫苗类型、剂型、年龄层和最终用户划分）—2025-2032 年全球预测

Travel Vaccines Market by Vaccine Type, Form, Age Group, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，旅行疫苗市场将成长 200 亿美元，复合年增长率为 10.36%。

主要市场统计数据
基准年2024年 90.9亿美元
预计2025年 100.1亿美元
预测年份：2032年 200亿美元
复合年增长率（%） 10.36%

简洁而权威的框架解释了为什么随着旅行模式的增加和旅行者期望的变化，旅行疫苗接种仍然至关重要

随着跨境旅行的恢復和多样化，旅行相关疫苗接种已成为一项至关重要的公共卫生干预措施。旅行前接种疫苗可以预防与旅游、商务旅行、出国目的地和人道主义部署相关的疫苗可预防疾病的传播，从而保护旅行者本人和更广泛的目的地社区。当旅客在准备旅行时，会参考临床指南、目的地特定的入境要求和数位健康资讯；这些因素正在影响对包括肝炎、流感和黄热病在内的关键疫苗的需求模式。

临床医生和公共卫生部门不断根据新出现的流行病学数据和不断变化的旅行者特征调整疫苗通讯协定。医疗旅游和国际任务的增加推动了对便捷获取专用疫苗和可靠的暴露后预防措施的需求，尤其是针对狂犬病和伤寒等疾病。同时，消费者行为正转向便利和数位化服务，越来越多的旅客寻求远端医疗旅行前咨询、快速获取疫苗接种记录以及透过药局和线上管道付款。这些趋势凸显了整合临床指导、供应链韧性和患者导向的技术以提供可靠且便利的旅游疫苗接种服务的重要性。

科学创新、数位化和监管复杂性如何融合重塑全球旅行疫苗接种模式和相关人员策略

在疫苗科学的进步、数位医疗的整合以及塑造供应链的地缘政治力量的推动下，旅行疫苗接种格局正在发生重大变化。包括新平台和改进的低温运输解决方案在内的技术进步，使得疫苗製剂更加耐用且适应性更强，从而影响了疫苗接种计划、储存要求和分发方式。同时，用于疫苗接种记录保存、旅行前风险评估和预约安排的数位医疗工具正在再形成患者病人历程，并拓展传统临床环境之外的网路基地台。

不同司法管辖区的监管一致性正在提高，但仍不均衡，这促使行业相关人员采取更灵活的合规策略，并投资于跨境资料互通性。同时，公众对疫苗安全性和有效性的审查日益严格，这推动了临床医生和製造商之间清晰、基于证据的沟通需求。因此，各组织正在优先考虑建立信任的措施、透明的供应链实践以及与当地医疗保健提供者的伙伴关係，以确保在疫情风险发生变化时能够做好准备并快速回应。这种结构性转变需要一种更一体化的方法，将科学创新、数位化和弹性物流结合，以有效满足旅行者的需求。

检验进口关税波动对旅游疫苗接种网路采购、低温运输物流和服务提供的连锁反应

贸易和海关制度的政策变化可能会对支持旅行疫苗接种计划的疫苗及相关物资的物流和供应产生重大影响。随着疫苗成分、包装材料和低温运输设备的进口关税上调，整个供应链的相关人员会调整其采购和库存策略，以消化成本压力或保护净利率。製造商和经销商可能会重新评估供应商合同，加快本地化进程，或优先储备关键投入品，以缓解供应中断的影响。

这些调整也将波及营运流动诊所、医院疫苗接种计画和零售药局管道的服务供应商。营业利润率较低的诊所可能会重新定价其服务，协商不同的供应条款，并儘可能转向采购国内替代品。同时，货运和物流合作伙伴必须调整路线和仓储策略，以控製成本，同时保持对温度敏感的完整性。从策略角度来看，持续的关税波动鼓励相关人员实现供应商多元化，提高采购透明度，并积极与政策制定者合作，以明确豁免条款和统一标准。事实上，贸易政策波动强化了在临床、商业和监管领域制定应急计画的必要性，以维持可靠的旅游疫苗及相关服务。

实际可行的细分洞察，强调疫苗类型、交付方式、年龄层和最终用户管道必须如何体现在差异化的临床和商业策略中

细緻地了解细分市场对于协调整个旅行疫苗接种生态系统的临床指导、分发方法和商业策略至关重要。疫苗类型组合至关重要，因为不同的病原体和疫苗接种方案（包括甲型肝炎、乙型肝炎、流感、脑膜炎球菌病菌感染、狂犬病、伤寒和黄热病）在临床紧迫性、旅行前接种时间和储存注意事项方面有所不同。虽然注射剂型因其有效性和既定的给药方案在临床实践中占主导地位，但口服疫苗为某些旅行者群体提供了替代途径，并有助于在资源匮乏和偏远地区推广。

成年旅客通常需要定期加强注射和针对出国目的地的疫苗接种，而儿童旅客则需要根据年龄选择合适的剂量、知情同意途径，并纳入常规儿童免疫接种计画。终端用户细分会影响疫苗的分发和获取：医院和诊所负责处理复杂的临床病例和专科疫苗接种，药房提供便捷的门诊就诊和续药服务，旅行诊所负责协调旅行前风险评估和多剂量接种计划，而在线药房则通过宅配和数字记录同步来扩大范围。透过根据这些细分维度调整产品系列、服务模式和患者参与策略，相关人员可以提高覆盖率，减少疫苗接种流失，并改善整体旅客体验。

美洲、欧洲、中东和非洲以及亚太市场的区域动态及其对旅客疫苗供应的实际影响

地理因素决定了疾病的流行程度、法律规范和服务提供模式，因此需要针对特定区域制定旅行者疫苗接种方案。在美洲，公共卫生系统和私人医疗机构正在合作应对南美洲部分地区的地方性疾病风险，例如黄热病，并支持与旅行模式相契合的大规模季节性流感防治宣传活动。该地区还展示了先进的分销网络，并日益普及数位健康证书，为跨区域旅行的旅客提供更无缝的旅行前通关和疫苗接种后文件记录。

欧洲、中东和非洲的监管环境各异，临床能力也参差不齐。虽然一些欧洲国家维持严格的旅行前咨询服务和集中疫苗接种计划，但非洲部分地区在低温运输基础设施和获得专用疫苗方面持续面临挑战。中东是客流量大的关键中继站，更凸显了疫苗接种验证和疫情防范的重要性。亚太地区的特点是部分市场製造能力强大，出境观光需求不断增长，某些次区域持续存在伤寒和狂犬病等地方性疾病问题。该地区的数位医疗应用和私营部门创新也呈现快速成长，支持透过药局和远端医疗旅游诊所扩大医疗服务覆盖范围。了解这些地区差异可以更有效地分配临床资源、有针对性的公共卫生讯息讯息，并建立反映当地需求和能力的策略伙伴关係。

领先的製造商、经销商和服务提供者如何重组其投资组合、伙伴关係和营运弹性，以确保旅游疫苗接种的部署

行业参与者正在透过调整产品组合、扩大经销伙伴以及投资製造和物流能力来应对临床需求和商业性机会。领先的疫苗製造商和产品创新者正在扩展开发平臺，以应对旅行相关的病原体多样性，并提高製剂稳定性和给药便利性。同时，经销商和服务提供者正在与专业的旅行诊所和药房网路建立更紧密的合作，以简化预约安排、低温运输处理和记录保存流程。

商业策略越来越注重韧性和灵活性。企业正在探索产能共享协议、区域灌装和成品营运以及分级定价机制，以应对采购的差异性。与数位平台提供者建立策略联盟，可实现全面旅行前评估、自动多剂量提醒以及在照护现场无缝验证疫苗接种状态。此外，品质保证和监管准备仍然是企业计划的核心，企业正在投资强大的药物安全检测和市场支持，以维护临床医生的信心并应对复杂的跨司法管辖区核准途径。

为产业领导者提供切实可行的优先策略行动，以增强供应弹性、数位存取和相关人员协作

旅行疫苗生态系统的领导者应优先考虑一系列切实可行的行动，以加强临床服务的提供和商业性可行性。首先，投资供应链冗余和低温运输优化，以降低贸易政策衝击和物流中断带来的脆弱性。其次，透过实施可互通的疫苗接种记录、远端医疗旅行前评估以及自动预约和用药提醒，加速整个旅行者旅程的数位整合，以提高接种率并最大限度地减少错失良机。

第三，根据疫苗类型、剂型、年龄层和最终用户特征客製化产品类型和分销管道，从而根据细分市场和本地需求客製化参与模式。第四，透过在製造商、经销商、旅行诊所和药房网络之间建立策略伙伴关係，加强相关人员合作，从而协调应对疫情风险并简化患者获取疫苗的流程。第五，加强公众传播策略，透过基于证据的讯息通讯、临床医生培训以及针对高风险旅行群体的有针对性的推广工作，解决犹豫不决的问题。最后，将监管和政策参与纳入计划，以影响关税和贸易谈判，尽可能争取豁免，并支持统一的标准，以促进疫苗跨境流动和核准。

结合初步访谈、政策审查和供应链分析的严格混合方法研究途径为旅行疫苗接种提供了实用见解

这些见解背后的研究采用了混合方法，旨在了解旅行疫苗接种的临床、操作和政策层面。主要定性访谈对象包括临床医生、旅游医学专家、供应链经理和监管专家，旨在收集有关服务提供挑战和适应性调整的第一手资料。此外，还整合了来自同行评审文献、公共卫生机构指南、贸易政策文件和物流报告的二手讯息，以检验临床路径、储存要求以及影响跨境疫苗运输的监管环境。

我们的分析方法将访谈记录的主题分析与供应链图谱结合，对重点地区进行比较性政策审查。三角测量程序确保报告结果与多个独立资讯来源一致，且结论反映的是趋同证据，而非单一资讯来源的假设。我们也考虑了调查方法的限制。虽然定性的深入探索提供了详细的营运讯息，相关人员的观点可能因市场和亚群而异，监管条件也可能因政策的快速变化而改变。为了解决这个问题，我们的研究与临床顾问和物流合作伙伴共同製定了持续的检验查核点，以确保洞察的实用性和时效性。

结论性综合结果强调了维持疫苗接种管道、增强抵御能力以及协调整个旅行疫苗接种生态系统中相关人员行动的战略重点

维持可靠且可近的旅游疫苗接种服务需要临床、商业和政策领域协调一致的行动。科学创新、数位转型和不断发展的贸易政策的汇聚力量，为管理疫苗供应和配送的相关人员创造了机会，也带来了脆弱性。有效应对这种环境需要积极主动的供应链策略、尊重差异化细分的有针对性的患者参与，以及反映当地流行病学和监管环境的客製化方法。

投资于免疫接种记录互通性、加强跨分销管道伙伴关係并与政策制定者进行建设性沟通的组织，将更有能力在风险变化时保持可及性并有效应对。重要的是，清晰的沟通和临床医生主导的教育仍然是维护公众信任和确保旅行者及时获得循证预防措施的基础。透过将策略远见与营运策略结合，相关人员可以推进有韧性且公平的免疫接种服务，同时保持旅行者照护的连续性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 采用mRNA平台技术加速长效型旅游疫苗的开发
  • 将数位疫苗接种护照和生物识别纳入旅行前健康通讯协定
  • 基于旅行者免疫遗传学和健康风险分析的个人化疫苗接种计划的兴起
  • 扩大官民合作关係，在新兴市场建立全球旅行疫苗接种中心
  • 引进新一代耐热疫苗，改善偏远地区低温运输物流
  • 对于前往多个国家的旅客来说，涵盖多种地方病的联合疫苗的需求日益增长。
  • 利用远端医疗平台提供旅行前远距咨询和疫苗推荐服务
  • 监管协调努力对简化跨境疫苗核准流程的影响
  • 为国际疫苗分销开发环保且永续的包装解决方案
  • 疫情后旅行激增对疫苗接种资源分配和优先策略的影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 旅行疫苗市场（依疫苗类型）

  • 甲型肝炎
  • B型肝炎
  • 流感
  • 脑膜炎奈瑟菌
  • 狂犬病
  • 伤寒
  • 黄热病

9. 旅行疫苗市场（按类型）

  • 注射
  • 口服

第十章旅行疫苗市场（依年龄层）

  • 成人
  • 孩子们

第 11 章。旅行疫苗市场（按最终用户划分）

  • 医院和诊所
  • 网路药局
  • 药局
  • 旅行诊所

12. 旅行疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章旅行疫苗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 旅行疫苗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Sanofi SA
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Valneva SE
    • Bavarian Nordic A/S
    • Bharat Biotech International Limited
    • Serum Institute of India Private Limited
    • Perusahaan Umum（Persero）Bio Farma
Product Code: MRR-0316851957A3

The Travel Vaccines Market is projected to grow by USD 20.00 billion at a CAGR of 10.36% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.09 billion
Estimated Year [2025] USD 10.01 billion
Forecast Year [2032] USD 20.00 billion
CAGR (%) 10.36%

A concise and authoritative framing of why travel immunization remains essential amid rising mobility patterns and shifting traveler expectations

Travel-related immunization remains a critical public health intervention as cross-border mobility resumes and diversifies. Pre-travel vaccination practices protect both individual travelers and broader host communities by limiting transmission of vaccine-preventable diseases associated with tourism, business travel, migration, and humanitarian deployments. Travelers consult an evolving mix of clinical guidelines, destination-specific entry requirements, and digital health credentials when preparing for trips, and these factors shape demand patterns for core vaccines such as hepatitis, influenza, and yellow fever.

Clinicians and public health authorities continue to adapt vaccination protocols to align with emerging epidemiological data and shifting traveler profiles. The growing prevalence of medical tourism and expatriate assignments has amplified the need for streamlined access to specialized vaccines and reliable post-exposure prophylaxis, particularly for diseases such as rabies and typhoid. Meanwhile, consumer behavior has shifted toward convenience and digital-enabled services, with more travelers seeking pre-travel consultations through telemedicine, rapid access to immunization records, and fulfillment via pharmacies and online channels. These dynamics underscore the importance of integrating clinical guidance, supply chain resilience, and patient-facing technologies to deliver dependable and accessible travel vaccination services.

How scientific innovation, digital enablement, and regulatory complexity are converging to reshape global travel vaccination delivery models and stakeholder strategies

The travel vaccine landscape is undergoing transformative shifts driven by advances in vaccine science, digital health integration, and the geopolitical context that shapes supply chains. Technological progress, including novel platforms and improved cold-chain solutions, is enabling more durable and adaptable vaccine formulations, which in turn affects vaccination schedules, storage requirements, and distribution approaches. Concurrently, digital health tools for vaccination record-keeping, pre-travel risk assessment, and appointment scheduling are reshaping patient journeys and expanding access points beyond traditional clinical settings.

Regulatory alignment across jurisdictions is improving but remains uneven, prompting industry stakeholders to adopt more flexible compliance strategies and to invest in cross-border data interoperability. In parallel, heightened public scrutiny around vaccine safety and efficacy has intensified the need for clear, evidence-based communication from clinicians and manufacturers. As a result, organizations are prioritizing trust-building measures, transparent supply-chain practices, and partnerships with local providers to ensure both preparedness and rapid response capability when outbreak risks change. These structural shifts collectively require a more integrated approach that combines scientific innovation, digital enablement, and resilient logistics to meet traveler needs effectively.

Examining the ripple effects of altered import tariff dynamics on procurement, cold-chain logistics, and service delivery across travel immunization networks

Policy changes in trade and tariff regimes can materially influence the logistics and availability of vaccines and associated supplies that support travel immunization programs. When import duties or tariffs increase on vaccine components, packaging materials, or cold-chain equipment, actors across the supply chain adjust procurement and inventory strategies to absorb cost pressures or to preserve margin. Manufacturers and distributors may re-evaluate supplier contracts, accelerate localization efforts, or prioritize stockpiling of critical inputs to mitigate disruption.

These adjustments cascade to service providers who operate travel clinics, hospital immunization programs, and retail pharmacy channels. Clinics with narrow operating margins may revise service pricing, negotiate different supply terms, or shift sourcing toward domestically produced alternatives where feasible. At the same time, freight and logistics partners must adapt routing and warehousing strategies to maintain temperature-sensitive integrity while controlling costs. From a strategic standpoint, sustained tariff changes prompt stakeholders to strengthen vendor diversification, increase transparency in procurement, and engage proactively with policymakers to clarify exemptions and harmonized standards. In effect, trade policy volatility amplifies the need for contingency planning across clinical, commercial, and regulatory frontiers to maintain reliable access to travel vaccines and related services.

Actionable segmentation insights that clarify how vaccine type, delivery form, age groups, and end-user channels must inform differentiated clinical and commercial strategies

A nuanced understanding of segmentation is essential for tailoring clinical guidance, distribution approaches, and commercial strategies across the travel vaccination ecosystem. Vaccine type composition matters because different pathogens and immunization regimens-such as those for hepatitis A and B, influenza, meningococcal disease, rabies, typhoid, and yellow fever-carry distinct clinical urgency, pre-travel timing, and storage considerations; therefore, supply prioritization and clinician workflows must reflect these clinical differences. Form factors influence delivery logistics and patient preference, as injectable formulations dominate in clinical settings due to efficacy and established administration protocols, while oral vaccines offer alternative pathways for certain traveler groups and can ease outreach in low-resource or remote scenarios.

Age group segmentation creates divergent clinical pathways and communication needs; adult travelers commonly require routine boosters or destination-specific immunizations, whereas pediatric travelers demand age-appropriate dosing, consent pathways, and integration with routine childhood vaccination schedules. End-user segmentation affects distribution and access: hospitals and clinics handle complex clinical cases and specialist immunizations, pharmacies offer convenient walk-in access and replenishment, travel clinics provide tailored pre-travel risk assessment and multi-dose schedules, and online pharmacies extend reach through home delivery and digital record synchronization. By aligning product portfolios, service models, and patient engagement tactics to these segmentation dimensions, stakeholders can enhance coverage, reduce missed opportunities for vaccination, and improve the overall traveler experience.

Regional dynamics and practical implications for travel vaccine delivery across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Geographic context shapes disease prevalence, regulatory frameworks, and service delivery models, requiring region-specific approaches to travel vaccination. In the Americas, public health systems and private providers coordinate to address endemic risks such as yellow fever in parts of South America and to support large-scale seasonal influenza campaigns that intersect with travel patterns. This region also demonstrates advanced distribution networks and a growing adoption of digital health credentials, enabling more seamless pre-travel clearance and post-vaccination documentation for travelers moving between subregions.

Europe, the Middle East, and Africa present a diverse regulatory landscape and a wide range of clinical capacities. Several European countries maintain rigorous pre-travel advisory services and centralized vaccination programs, while parts of Africa face persistent challenges related to cold-chain infrastructure and access to specialized vaccines. The Middle East is an important transit corridor with high passenger throughput, which elevates the importance of vaccination verification and outbreak preparedness. Asia-Pacific is characterized by robust manufacturing capability in some markets, rising demand driven by outbound tourism, and persistent endemic concerns such as typhoid and rabies in specific subregions. The region also shows rapid growth in digital health adoption and private-sector innovation, which supports expanded access through pharmacies and telehealth-enabled travel clinics. Understanding these regional differences enables more effective allocation of clinical resources, targeted public health messaging, and strategic partnerships that reflect local needs and capacities.

How leading manufacturers, distributors, and service providers are reshaping portfolios, partnerships, and operational resilience to secure travel vaccination delivery

Industry participants are responding to both clinical imperatives and commercial opportunities by adapting portfolios, extending distribution partnerships, and investing in manufacturing and logistics capabilities. Leading vaccine producers and product innovators are expanding their development pipelines to address travel-related pathogen diversity and to improve formulation stability and administration convenience. At the same time, distributors and service providers are forging closer collaborations with specialty travel clinics and pharmacy networks to streamline appointment scheduling, cold-chain handling, and record-keeping.

Commercial strategies increasingly emphasize resilience and flexibility: companies are exploring capacity-sharing agreements, regional fill-and-finish operations, and tiered pricing mechanisms to address procurement variability. Strategic alliances with digital platform providers enable integrated pre-travel assessments, automated reminders for multi-dose series, and smoother verification of immunization status at points of care. Additionally, quality assurance and regulatory readiness remain central to company planning, with firms investing in robust pharmacovigilance and in-market support to sustain clinician confidence and to navigate complex approval pathways across jurisdictions.

Practical and prioritized strategic actions that industry leaders should implement to reinforce supply resilience, digital access, and targeted stakeholder collaboration

Leaders in the travel vaccine ecosystem should prioritize a set of practical actions that strengthen clinical service delivery and commercial viability. First, invest in supply chain redundancy and cold-chain optimization to reduce vulnerability to trade policy shocks and logistical disruptions; this includes establishing alternative suppliers, regional fill-and-finish capabilities, and transparent inventory management systems. Second, accelerate digital integration across the traveler journey by deploying interoperable vaccination records, telemedicine pre-travel assessments, and automated appointment and dosing reminders to increase uptake and minimize missed opportunities.

Third, tailor engagement models to segmentation and regional needs by aligning product offerings and distribution channels with vaccine type, form, age group, and end-user characteristics. Fourth, enhance stakeholder collaboration by building strategic partnerships among manufacturers, distributors, travel clinics, and pharmacy networks to enable coordinated response to outbreak risks and to streamline patient access. Fifth, strengthen public communication strategies to address hesitancy through evidence-based messaging, clinician training, and targeted outreach for high-risk traveler cohorts. Finally, embed regulatory and policy engagement in planning to influence tariff and trade discussions, secure exemptions where possible, and support harmonized standards that facilitate cross-border vaccine movement and recognition.

A rigorous mixed-methods research approach combining primary interviews, policy review, and supply-chain analysis to underpin practical travel vaccination insights

The research underpinning these insights employed a mixed-methods approach designed to capture clinical, operational, and policy dimensions of travel immunization. Primary qualitative interviews were conducted with clinicians, travel-medicine specialists, supply-chain managers, and regulatory experts to gather direct observations about service delivery challenges and adaptation strategies. Secondary source synthesis drew on peer-reviewed literature, public health agency guidance, trade policy documents, and logistics reports to validate clinical pathways, storage requirements, and the regulatory context affecting cross-border vaccine movement.

Analytical methods combined thematic analysis of interview transcripts with supply-chain mapping and comparative policy review across the principal regions. Triangulation procedures ensured that reported findings aligned with multiple independent information sources and that conclusions reflected convergent evidence rather than single-source assumptions. The methodology also accounted for limitations: while qualitative depth provided rich operational detail, stakeholder perspectives may vary by market and subpopulation, and rapid policy changes can alter regulatory conditions. To address this, the research incorporated continuous validation checkpoints with clinical advisors and logistics partners to ensure practical relevance and timeliness of insights.

Conclusive synthesis emphasizing strategic priorities for preserving access, building resilience, and aligning stakeholder actions across the travel vaccination ecosystem

Maintaining reliable and accessible travel immunization services requires coordinated action across clinical, commercial, and policy domains. The converging forces of scientific innovation, digital transformation, and evolving trade policy create both opportunities and vulnerabilities for stakeholders who manage vaccine supply and delivery. Effectively navigating this environment demands proactive supply-chain strategies, targeted patient engagement that respects segmentation differences, and regionally tailored approaches that reflect local epidemiology and regulatory conditions.

Organizations that invest in interoperability of vaccination records, strengthen partnerships across distribution channels, and engage constructively with policymakers will be better positioned to sustain access and to respond efficiently when risks change. Importantly, clear communication and clinician-led education remain foundational for maintaining public trust and for ensuring that travelers receive timely, evidence-based protection. By aligning operational tactics with strategic foresight, stakeholders can preserve continuity of care for travelers while advancing resilient and equitable vaccination services.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of mRNA platform technologies to accelerate development of long-lasting travel vaccines
  • 5.2. Integration of digital vaccination passports and biometric verification in pre-travel health protocols
  • 5.3. Rise of personalized vaccination schedules based on traveler immunogenetic and health risk profiling
  • 5.4. Expansion of public private partnerships to establish global travel vaccination hubs in emerging markets
  • 5.5. Implementation of next generation thermostable vaccines to improve cold chain logistics in remote destinations
  • 5.6. Growing demand for combination vaccines covering multiple endemic diseases for multi-country itineraries
  • 5.7. Use of telemedicine platforms for remote pre-travel consultation and vaccine recommendation services
  • 5.8. Impact of regulatory harmonization efforts on streamlining cross border vaccine approval processes
  • 5.9. Development of eco-friendly and sustainable packaging solutions for international vaccine distribution
  • 5.10. Influence of post-pandemic travel surges on immunization resource allocation and prioritization strategies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Travel Vaccines Market, by Vaccine Type

  • 8.1. Hepatitis A
  • 8.2. Hepatitis B
  • 8.3. Influenza
  • 8.4. Meningococcal
  • 8.5. Rabies
  • 8.6. Typhoid
  • 8.7. Yellow Fever

9. Travel Vaccines Market, by Form

  • 9.1. Injectable
  • 9.2. Oral

10. Travel Vaccines Market, by Age Group

  • 10.1. Adult
  • 10.2. Pediatric

11. Travel Vaccines Market, by End User

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacies
  • 11.3. Pharmacies
  • 11.4. Travel Clinics

12. Travel Vaccines Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Travel Vaccines Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Travel Vaccines Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Sanofi S.A.
    • 15.3.2. GlaxoSmithKline plc
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Pfizer Inc.
    • 15.3.5. Takeda Pharmaceutical Company Limited
    • 15.3.6. Valneva SE
    • 15.3.7. Bavarian Nordic A/S
    • 15.3.8. Bharat Biotech International Limited
    • 15.3.9. Serum Institute of India Private Limited
    • 15.3.10. Perusahaan Umum (Persero) Bio Farma

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 130. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 160. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 170. AFRICA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 192. ASEAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GCC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. GCC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 202. GCC TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 203. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GCC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. GCC TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 222. BRICS TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. G7 TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. G7 TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 232. G7 TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 233. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. G7 TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. G7 TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NATO TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NATO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 242. NATO TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 243. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. NATO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. NATO TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 253. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. CANADA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 261. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MEXICO TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 268. MEXICO TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 269. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. BRAZIL TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 277. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 284. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GERMANY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 292. GERMANY TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 293. GERMANY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GERMANY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. FRANCE TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 300. FRANCE TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 301. FRANCE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 302. FRANCE TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. RUSSIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 308. RUSSIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 309. RUSSIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 310. RUSSIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. ITALY TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 316. ITALY TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 317. ITALY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. ITALY TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. SPAIN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 324. SPAIN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 325. SPAIN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. SPAIN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 332. CHINA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 333. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 334. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. INDIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 340. INDIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 341. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. JAPAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 348. JAPAN TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 349. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 350. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 355. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 356. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 357. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 358. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 362. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 364. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 365. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 366. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 367. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 368. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 369. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 370. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024